The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution   Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)     Thomas Powles Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche   Jonathan Rosenberg Honoraria - Astellas Pharma; MashupMD; Pfizer Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Generate Biomedicines; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Tyra Biosciences Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Lilly; Pfizer; Seagen (Inst) Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst) Travel, Accommodations, Expenses - Astellas Pharma (OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology; Kalivir Immunotherapeutics   Shilpa Gupta Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; Johnson & Johnson/Janssen; Merck; Natera; Novartis; Pfizer Research Funding - Acrivon Therapeutics (Inst); Amgen (Inst); Bristol Myers Squibb Foundation (Inst); Convergent Therapeutics (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Tyra Biosciences (Inst) Patents, Royalties, Other Intellectual Property - UpToDate author royalty Travel, Accommodations, Expenses - Astellas Pharma; Merck; Pfizer   Yohann Loriot Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst) Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen   Marc-Oliver Grimm Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Cilag; Merck Serono; MSD; Novartis Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen Cilag; Merck Serono; MSD; Novartis; Pfizer; Roche Research Funding - Bayer/Vital (Inst); Bristol-Myers Squibb (Inst); Intuitive Surgical (Inst) Travel, Accommodations, Expenses - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Gilead Sciences; Ipsen; Janssen Cilag; Merck Serono; MSD; Novartis; Pfizer   Julius Strauss Employment - Bristol-Myers Squibb Stock and Other Ownership Interests - Bristol-Myers Squibb Travel, Accommodations, Expenses - Bristol-Myers Squibb   Arnold Gelb Employment - Bristol Myers Squibb Stock and Other Ownership Interests - Bristol Myers Squibb Patents, Royalties, Other Intellectual Property - LAG-3 Antagonist Therapy for Hematological Cancer (Inst)   Sean McLean Employment - Bristol Myers Squibb Stock and Other Ownership Interests - Bristol-Myers Squibb Travel, Accommodations, Expenses - Bristol Myers Squibb   Luoying Yang Employment - Bristol-Myers Squibb Stock and Other Ownership Interests - Bristol-Myers Squibb   Maurice Lobo Employment - Bristol-Myers Squibb/Celgene Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene   David Perez Callejo Employment - Bristol-Myers Squibb; Roche Stock and Other Ownership Interests - Bristol Mers Squibb; Roche   Jimmy Zhao Employment - Systimmune Stock and Other Ownership Interests - Lilly   Jonathan Cheng Employment - Bristol-Myers Squibb/Celgene; Systimmune Stock and Other Ownership Interests - Bristol Myers Squibb Foundation; Merck; Systimmune   Matthew Galsky Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst) Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792